{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:30:12Z","timestamp":1782307812733,"version":"3.54.5"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T00:00:00Z","timestamp":1549670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,9]]},"DOI":"10.1093\/ajhp\/zxy050","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T03:14:19Z","timestamp":1549682059000},"page":"268-274","source":"Crossref","is-referenced-by-count":4,"title":["Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis"],"prefix":"10.1093","volume":"76","author":[{"given":"Nichole","family":"Sly","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Care, University of Iowa Hospitals & Clinics, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Gaspar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care, University of Iowa Hospitals & Clinics, Iowa City, IA"},{"name":"University of Iowa College of Pharmacy, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,9]]},"reference":[{"key":"2019061104493929900_CIT0001","article-title":"SEER 18, 2009-2013","author":"National Cancer Institute","year":"2017"},{"key":"2019061104493929900_CIT0002","author":"National Comprehensive Cancer Network"},{"key":"2019061104493929900_CIT0003","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"2019061104493929900_CIT0004","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1182\/blood.V88.10.3987.bloodjournal88103987","article-title":"Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of bcl-2 and bax","volume":"88","author":"Lisovsky","year":"1996","journal-title":"Blood"},{"key":"2019061104493929900_CIT0005","doi-asserted-by":"crossref","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","article-title":"FLT3 as a therapeutic target in AML: still challenging after all these years","volume":"116","author":"Kindler","year":"2010","journal-title":"Blood"},{"key":"2019061104493929900_CIT0006","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study","volume":"61","author":"Whitman","year":"2001","journal-title":"Cancer Res"},{"key":"2019061104493929900_CIT0007","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.thj.6200196","article-title":"Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16)","volume":"3","author":"Kainz","year":"2002","journal-title":"Hematol J"},{"key":"2019061104493929900_CIT0008","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2007-08-107946","article-title":"FLT3 D835\/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications","volume":"111","author":"Whitman","year":"2008","journal-title":"Blood"},{"key":"2019061104493929900_CIT0009","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"2019061104493929900_CIT0010","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group ULM","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"key":"2019061104493929900_CIT0011","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"2019061104493929900_CIT0012","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/sj.leu.2403838","article-title":"Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis","volume":"19","author":"Yanada","year":"2005","journal-title":"Leukemia"},{"key":"2019061104493929900_CIT0013","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"2019061104493929900_CIT0014","author":"Rydapt (midostaurin)","year":"2017"},{"key":"2019061104493929900_CIT0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/978-0-387-73744-7_18","article-title":"Systemic mastocytosis","volume-title":"Rare hematological malignancies","author":"Valent","year":"2008"},{"key":"2019061104493929900_CIT0016","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk Res"},{"key":"2019061104493929900_CIT0017","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"key":"2019061104493929900_CIT0018","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"2019061104493929900_CIT0019","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.116.072744","article-title":"Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug","volume":"45","author":"He","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"2019061104493929900_CIT0020","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","article-title":"Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers","volume":"72","author":"Dutreix","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019061104493929900_CIT0021","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1182\/blood.V124.21.5284.5284","article-title":"Decitabine and sorafenib therapy in patients with FLT3-ITD mutant acute myeloid leukemia is associated with high response rates\u2014a single institute experience","volume":"124","author":"Muppidi","year":"2014","journal-title":"Blood"},{"key":"2019061104493929900_CIT0022","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","article-title":"Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation","volume":"121","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"2019061104493929900_CIT0023","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1200\/JCO.2009.25.4888","article-title":"Phase I\/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia","volume":"28","author":"Ravandi","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019061104493929900_CIT0024","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3109\/10428194.2011.637210","article-title":"Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia","volume":"53","author":"R\u00f6llig","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2019061104493929900_CIT0025","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"2019061104493929900_CIT0026","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2019061104493929900_CIT0027","unstructured":"Larson RA , MandrekarSJ, SanfordBLet al An analysis of maintenance therapy and post-midostaurin outcomes in the international prospective randomized, placebo-controlled, doubleblind trial (CALGB 10603\/RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations. Oral presentation at: American Society of Hematology 59th Annual Meeting & Exposition. December 9\u201312, 2017; Atlanta, GA."},{"key":"2019061104493929900_CIT0028","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2133.1995.tb08689.x","article-title":"Interferon-alpha in combination with corticosteroids improves systemic mast cell disease","volume":"132","author":"Delaporte","year":"1995","journal-title":"Br J Dermatol"},{"key":"2019061104493929900_CIT0029","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"2019061104493929900_CIT0030","author":"Gleevec (imatinib mesylate)","year":"2015"},{"key":"2019061104493929900_CIT0031","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"2019061104493929900_CIT0032","volume-title":"Lexi-Drugs. Lexicomp","author":"Midostaurin"},{"key":"2019061104493929900_CIT0033","author":"National Pharmaceutical Services","year":"2017"},{"key":"2019061104493929900_CIT0034","unstructured":"ClinicalTrials.gov. Midostaurin (PKC412) for locally advanced rectal cancer. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01282502 (accessed 2017 Sep 25)."},{"key":"2019061104493929900_CIT0035","unstructured":"ClinicalTrials.gov. Phase I combination of midostaurin, bortezomib, and chemo in relapsed\/refractory acute myeloid leukemia. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01174888 (accessed 2017 Sep 25)."},{"key":"2019061104493929900_CIT0036","unstructured":"ClinicalTrials.gov. Midostaurin and decitabine in treating older patients with newly diagnosed acute myeloid leukemia and FLT3 mutation. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02634827 (accessed 2017 Sep 25)."},{"key":"2019061104493929900_CIT0037","unstructured":"ClinicalTrials.gov. Combination of decitabine and midostaurin in patients older than 60 with newly diagnosed or relapsed refractory acute myeloid leukemiahttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT01130662 (accessed 2017 Sep 25)."},{"key":"2019061104493929900_CIT0038","unstructured":"ClinicalTrials.gov. Phase II midostaurin in aggressive systemic mastocytosis and mast cell leukemiahttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00233454 (accessed 2017 Sep 25)."},{"key":"2019061104493929900_CIT0039","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/onc.2010.273","article-title":"Drug resistance in mutant FLT3-positive AML","volume":"29","author":"Weisberg","year":"2010","journal-title":"Oncogene"},{"key":"2019061104493929900_CIT0040","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clml.2016.06.002","article-title":"FLT3 inhibitors for treating acute myeloid leukemia","volume":"16","author":"Hassanein","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019061104493929900_CIT0041","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1535-7163.MCT-14-0388","article-title":"AMG 925 is a dual FLT3\/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia","volume":"14","author":"Li","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2019061104493929900_CIT0042","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1038\/bcj.2013.40","article-title":"Overcoming AC220 resistance of FLT3-ITD by SAR302503","volume":"3","author":"Kesarwani","year":"2013","journal-title":"Blood Cancer J"},{"key":"2019061104493929900_CIT0043","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1365-2141.2012.09085.x","article-title":"Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation","volume":"157","author":"Zirm","year":"2012","journal-title":"Br J Haematol"},{"key":"2019061104493929900_CIT0044","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2013-04-493916","article-title":"G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia","volume":"123","author":"Lee","year":"2014","journal-title":"Blood"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/5\/268\/28791410\/zxy050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T12:36:26Z","timestamp":1573907786000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/5\/268\/5310474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,9]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,2,9]]},"published-print":{"date-parts":[[2019,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxy050","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,1]]},"published":{"date-parts":[[2019,2,9]]}}}